All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Persistent infection with human papillomavirus (HPV) is a virtually necessary cause of cervical cancer \[[@pone.0156215.ref001]\]. One of the most common curable sexually transmitted infections (STI) worldwide *Chlamydia trachomatis* has been associated with an increased risk of cervical cancer \[[@pone.0156215.ref002]--[@pone.0156215.ref004]\]. While the most of the studies are focused on squamous cervical carcinoma, there was more limited power to study cervical adenocarcinoma, but no association was found \[[@pone.0156215.ref003],[@pone.0156215.ref005]\], which is surprising as *C*. *trachomatis* primarily infects glandular cells \[[@pone.0156215.ref002]\]. Some studies relied on seroepidemiology, where it is difficult to rule out residual confounding completely \[[@pone.0156215.ref001]\]. One study reported no detection of *C*. *trachomatis* DNA in 71 archived formalin-fixed paraffin-embedded tissues of cervical adenocarcinoma (5), but cross-sectional studies are less informative than longitudinal studies \[[@pone.0156215.ref001]\] and *C*. *trachomatis* has only been detected in samples taken many years before the cancer, not close to the diagnosis \[[@pone.0156215.ref002]\].

We previously reported a large prospective study of cervical adenocarcinoma that established a strong association with HPV present many years before cancer diagnosis (6). We now wished to use this large prospective study to investigate possible associations between *C*. *trachomatis* and cervical adenocarcinoma.

Materials and Methods {#sec007}
=====================

Detailed characteristics of the study have been reported previously \[[@pone.0156215.ref006]\]. A total of 1,553 β-globin-positive cervical smears collected during the pre-HPV vaccine era (1969--2002) in Sweden before the development of adenocarcinoma *in-situ* (AIS, 133 cases; mean age at entry and diagnosis: 28 and 37 years, respectively) or invasive cervical adenocarcinoma (AC, 170 cases; 37/43 years) and matched controls (128 and 169; 29/37 and 37/43 years, respectively) were tested for the presence of *C*. *trachomatis* and 19 mucosal HPV types (HPV-6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68a and 68b, 70, 73 and 82), using a validated type-specific PCR bead-based multiplex genotyping (TS-MPG, IARC, Lyon, France) assay that combines multiplex polymerase chain reaction (PCR) and bead-based Luminex technology (Luminex Corp., Austin, TX, USA), as described elsewhere \[[@pone.0156215.ref007],[@pone.0156215.ref008]\].

Results {#sec008}
=======

In total, 1.7% (26/1553) of samples were positive for *C*. *trachomatis* ([Table 1](#pone.0156215.t001){ref-type="table"}). The 26 samples corresponded to only 21 distinct subjects. No major difference in *C*. *trachomatis*-positivity was observed between the outcomes and case-control status; the odds-ratios (ORs) for the association between chlamydia infection in the first collected smear and subsequent adenocarcinoma were 1.25 for AIS (95% CI 0.34--4.65) and 3.0 for AC (95%CI 0.31--28.84); ORs associated with chlamydia infection in the last smear before diagnosis were not estimable due to the lack of exposed cases (AIS) and controls (AC), respectively ([Table 2](#pone.0156215.t002){ref-type="table"}). The full data set is available as Supplementary Information ([S1 Table](#pone.0156215.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0156215.t001

###### Study population and distribution of *C*. *trachomatis* positive smears between cases and controls, for all β-globin-positive smears collected in the study.

![](pone.0156215.t001){#pone.0156215.t001g}

                                                             Adenocarcinoma *in situ* (AIS)   Invasive adenocarcinoma (AC)                     
  ---------------------------------------------------------- -------------------------------- ------------------------------ ----------------- -----------------
  Subjects                                                   133                              128                            170               169
  Age at first smear[^a^](#t001fn001){ref-type="table-fn"}   28 (17--71)                      29 (16--71)                    37 (17--82)       37 (17--82)
  Age at last smear[^a^](#t001fn001){ref-type="table-fn"}    33 (17--72)                      34 (17--71)                    41 (20--82)       39 (20--82)
  Age at diagnosis[^a^](#t001fn001){ref-type="table-fn"}     37 (20--75)                      37 (20--75)                    43 (25--88)       43 (25--89)
  Time in study[^a^](#t001fn001){ref-type="table-fn"}        7.4 (0.1--27.0)                  8.0 (0.2--25.9)                6.1 (0.0--21.1)   6.0 (0.1--22.2)
  Smears[^b^](#t001fn002){ref-type="table-fn"}               425 (100)                        332 (100)                      422 (100)         374 (100)
  HPV positive[^b^](#t001fn002){ref-type="table-fn"}         323 (76)                         93 (28)                        267 (63)          87 (23)
  CT positive[^b^](#t001fn002){ref-type="table-fn"}          10 (2.4)                         7 (2.1)                        7 (1.7)           2 (0.5)

^a^ Reported in years: median (minimum-maximum)

^b^ Reported as count (percentage)

CT--*C*. *trachomatis* HPV--Human papillomavirus (any strain)

10.1371/journal.pone.0156215.t002

###### Risk of cervical adenocarcinoma given by *C*. *trachomatis* infection in the first and last smear, calculated as odds ratio via conditional logistic regression where possible.

![](pone.0156215.t002){#pone.0156215.t002g}

        Smear   Matched cases/controls   Exposed cases/controls[^a^](#t002fn001){ref-type="table-fn"}   Odds ratio                                 95% Conf.int.
  ----- ------- ------------------------ -------------------------------------------------------------- ------------------------------------------ ------------------------------------------
  AIS   First   128                      5/4                                                            1.25                                       0.34--4.65
        Last    128                      0/2                                                            NA[^b^](#t002fn002){ref-type="table-fn"}   NA[^b^](#t002fn002){ref-type="table-fn"}
  AC    First   158                      3/1                                                            3.00                                       0.31--28.84
        Last    158                      2/0                                                            NA[^b^](#t002fn002){ref-type="table-fn"}   NA[^b^](#t002fn002){ref-type="table-fn"}

^a^ Matched case/control pairs that differ in exposure and contribute to the OR estimation, reported as exposed cases/exposed controls

^b^ Could not be calculated due to perfect separation (no exposed cases or controls)

Footnote: AIS--adenocarcinoma *in situ*, AC--adenocarcinoma

HPV-positivity was detected in 49.3% (n = 753) of *C*. *trachomatis*-negative and 65.4% (n = 17) *C*. *trachomatis*-positive samples. Because of the overall low numbers, a further analysis of possible interaction between *C*. *trachomatis* and HPV status was not feasible.

Discussion {#sec009}
==========

In the current largest prospective study to date of *C*. *trachomatis* and cervical adenocarcinoma, with a follow-up period of up to 26 years, *C*. *trachomatis* was not associated with increased risks of subsequent invasive adenocarcinoma (AC) and its precursor, adenocarcinoma *in situ* (AIS). The average age of participants in this study was above 30 years, and it is possible that co-infections/interactions between *C*. *trachomatis* and HPV, or other STI, may be of more relevance at earlier age and this may require further studying. A higher prevalence of HPV infections have been found in younger Italian women affected with a *C*. *trachomatis* chronic infection from a STI centre than in the ones from an assisted reproductive technology clinic \[[@pone.0156215.ref009]\]. HPV genotype distribution showed that mostly uncommon low risk genotypes were associated with *C*. *trachomatis* \[[@pone.0156215.ref010]\]. However, while Danish women who reported more than one Chlamydia infection had a statistically significantly increased risk of CIN3+, no association was found between *C*. *trachomatis* DNA and subsequent risk of CIN3+ among the ones who were HPV-positive or had a persistent HPV infection at baseline \[[@pone.0156215.ref011]\]. No association between *C*. *trachomatis* status, as assessed by DNA or IgG, and risk of cervical premalignancy, after controlling for carcinogenic HPV-positive status was found in a previous study from the United States \[[@pone.0156215.ref012]\], which suggested that positive associations between *C*. *trachomatis* and cervical premalignancy could have been caused, in part, by an increased susceptibility to HPV infection \[[@pone.0156215.ref012]\]. However, no studies have been done among the women with cervical adenocarcinoma and the present study is the first of this kind. Moreover, the reports of an interaction between *C*. *trachomatis* and HPV in squamous cell carcinoma of the cervix are mechanistically unexplained \[[@pone.0156215.ref001]\] and further studies on the co-factor role of genital microbiota in promoting malignancies, in particular in high-risk and younger populations, may be warranted.

Supporting Information {#sec010}
======================

###### The analysis dataset on the detection of *Chlamydia trachomatis* and human papillomavirus (HPV) infections in women with cervical adenocarcinoma.

SubjectID--unique subject identifier, RisksetID--unique risk set identifier, CaseStatus--case-control status (1 = case), AgeAtDiag--age at the time of diagnosis, HPVpos--HPV-positivity (1 = HPV-positive), CTpos--Chlamydia trachomatis-positivity (1 = Chlamydia-positive), AgeAtSmear--age at the time of collecting cervial smear).

(ODS)

###### 

Click here for additional data file.
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